{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:48:29Z","timestamp":1784717309571,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejca.2024.115160","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T04:06:58Z","timestamp":1734062818000},"page":"115160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma \u2013 Results of systematic literature research"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2516-5181","authenticated-orcid":false,"given":"Teresa","family":"Amaral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Nanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina Maria Serna","family":"Higuita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Berking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Mu\u00f1oz","family":"Couselo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Donia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Haushild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Jalving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Marquez-Rodas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Michelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Sobczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Flatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.115160_bib1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.21.02961","article-title":"Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated braf-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase ii trial","volume":"41","author":"Ascierto","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115160_bib2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced braf-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115160_bib3","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage iii melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115160_bib4","doi-asserted-by":"crossref","unstructured":"Long Georgina V, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Chiarion-Sileni V, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. New England Journal of Medicine.377:1813\u20131823.","DOI":"10.1056\/NEJMoa1708539"},{"key":"10.1016\/j.ejca.2024.115160_bib5","doi-asserted-by":"crossref","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas Helen J, Arance Ana M, Cowey CL, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. New England Journal of Medicine.377:1824\u20131835.","DOI":"10.1056\/NEJMoa1709030"},{"key":"10.1016\/j.ejca.2024.115160_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","article-title":"Survival of patients with advanced metastatic melanoma: the impact of novel therapies\u2013update 2017","volume":"83","author":"Ugurel","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115160_bib7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2020.02.021","article-title":"Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019","volume":"130","author":"Ugurel","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115160_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215426","article-title":"Application of electronic health record text mining: real-world tolerability, safety, and efficacy of adjuvant melanoma treatments","volume":"14","author":"van Laar","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2024.115160_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ijc.34462","article-title":"Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: data from two academic Italian institutions","volume":"153","author":"De Falco","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2024.115160_bib10","doi-asserted-by":"crossref","first-page":"11475","DOI":"10.1002\/cam4.5866","article-title":"Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: a real-world retrospective study from single center in China","volume":"12","author":"Zhong","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2024.115160_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15174384","article-title":"Modern approach to melanoma adjuvant treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF\/MEK targeted therapy: multicenter real-world report","volume":"15","author":"Placzke","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2024.115160_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007630","article-title":"Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG","volume":"11","author":"Haist","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2024.115160_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112957","article-title":"Adjuvant treatment and outcome of stage III melanoma patients: results of a multicenter real-world german dermatologic cooperative oncology group (DeCOG) study","volume":"191","author":"Lodde","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115160_bib14","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/jdv.18779","article-title":"Real-world outcomes using PD-1 antibodies and BRAF +\u2009MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland","volume":"37","author":"Schumann","year":"2023","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"key":"10.1016\/j.ejca.2024.115160_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/oncolo\/oyad223","article-title":"Adjuvant systemic therapies for resected stages iii and iv melanoma: a multi-center retrospective clinical study","volume":"29","author":"Rigo","year":"2024","journal-title":"oncologist"},{"key":"10.1016\/j.ejca.2024.115160_bib16","first-page":"65","article-title":"Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <em>BRAF<\/em> V","author":"Bai","year":"2023","journal-title":"600-Mutant Stage III Melanoma Defin Surg: a Multicent, Retrosp cohort Study eClinicalMedicine"},{"key":"10.1016\/j.ejca.2024.115160_bib17","unstructured":"Blank CU , Lucas MW , Scolyer RA , Wiel BAvd , Menzies AM , Lopez-Yurda M. , et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. New England Journal of Medicine.0."},{"key":"10.1016\/j.ejca.2024.115160_bib18","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115160_bib19","unstructured":"Long GV, Hauschild A, Santinami M, Kirkwood JM, Atkinson V, Mandala M, et al. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. New En9*0gland Journal of Medicine.0."},{"key":"10.1016\/j.ejca.2024.115160_bib20","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/0284186X.2020.1747636","article-title":"BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis","volume":"59","author":"Ny","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2024.115160_bib21","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-year analysis of adjuvant pembrolizumab or placebo in stage iii melanoma","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ejca.2024.115160_bib22","unstructured":"(EMA) EMA. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf. 2024."},{"key":"10.1016\/j.ejca.2024.115160_bib23","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III\/IV melanoma: 5-year efficacy and biomarker results from checkMate 238","volume":"29","author":"Larkin","year":"2023","journal-title":"Clin Cancer Res: J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2024.115160_bib24","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2159-8290.CD-21-1141","article-title":"Adjuvant pembrolizumab versus IFN\u03b12b or ipilimumab in resected high-risk melanoma","volume":"12","author":"Grossmann","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2024.115160_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103919","article-title":"Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: a systematic scoping review","volume":"183","author":"Egeler","year":"2023","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.ejca.2024.115160_bib26","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-upx2606","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.115160_bib27","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(21)00081-4","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Bottomley","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.115160_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113601","article-title":"Real-world health-related quality of life outcomes for patients with resected stage III\/IV melanoma treated with adjuvant anti-PD1 therapy","volume":"200","author":"Egeler","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115160_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194823","article-title":"Real-world effectiveness, safety, and health-related quality of life in patients receiving adjuvant nivolumab for melanoma in belgium and luxembourg: results of PRESERV MEL","volume":"15","author":"Rogiers","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2024.115160_bib30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/0284186X.2023.2165449","article-title":"Quality of life and mental health in real-world patients with resected stage III\/IV melanoma receiving adjuvant immunotherapy","volume":"62","author":"Pedersen","year":"2023","journal-title":"Acta Oncol (Stockh, Swed)"},{"key":"10.1016\/j.ejca.2024.115160_bib31","doi-asserted-by":"crossref","first-page":"9590","DOI":"10.1200\/JCO.2018.36.15_suppl.9590","article-title":"Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma","volume":"36","author":"Schadendorf","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115160_bib32","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41416-020-01121-y","article-title":"Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis","volume":"124","author":"Bhave","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2024.115160_bib33","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.annonc.2020.04.471","article-title":"Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy","volume":"31","author":"Owen","year":"2020","journal-title":"Ann Oncol: J Eur Soc Med Oncol \/ ESMO"},{"key":"10.1016\/j.ejca.2024.115160_bib34","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/jnci\/djad081","article-title":"Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study","volume":"115","author":"Helgadottir","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2024.115160_bib35","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab plus ipilimumab for treatment-na\u00efve metastatic uveal melanoma: an open-label, multicenter, phase ii trial by the Spanish multidisciplinary melanoma group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115160_bib36","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115160_bib37","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115160_bib38","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.annonc.2023.11.013","article-title":"Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis","volume":"35","author":"Piulats","year":"2024","journal-title":"Ann Oncol: J Eur Soc Med Oncol \/ ESMO"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924017672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924017672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T21:04:01Z","timestamp":1738875841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924017672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":38,"alternative-id":["S0959804924017672"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115160","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma \u2013 Results of systematic literature research","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115160","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115160"}}